These insights suggest that serum APOA-I levels could serve as a biomarker reflecting various aspects of CRC pathogenesis, including lipid dysregulation and inflammation, and might be relevant for understanding the mechanisms of cancer development, offering potential prognostic value and possibly informing therapeutic strategies. The gene discussed is APOA1; the disease is colorectal carcinoma.